Published in J Urol on February 01, 1976
Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiat Oncol (2007) 0.87
Primary squamous cell carcinoma of the prostate: a case report of a rare clinical entity. Future Sci OA (2015) 0.75
Superficial bladder cancer: progression and recurrence. J Urol (1983) 2.30
Delayed hypersensitivity in Hodgkin's disease. A study of 103 untreated patients. Am J Med (1972) 1.49
Immune alterations in Hodgkin's disease. Effect of delayed hypersensitivity and lymphocyte transformation on course and survival. Arch Intern Med (1973) 0.99
A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Cancer (1983) 0.94
Phytohemagglutinin-induced lymphocyte transformation: the relationship to prognosis of Hodgkin's disease. Blood (1972) 0.93
Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia. Cancer (1978) 0.92
Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer (1982) 0.87
Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat Rep (1981) 0.86
Pericardial effusions in patients with malignant diseases. Arch Intern Med (1975) 0.82
A financial analysis of Hodgkin lymphoma staging. Am J Public Health (1981) 0.81
ABVD treatment of MOPP failures in Hodgkin's disease: a re-examination of goals of salvage therapy. Cancer Treat Rep (1978) 0.81
Phase II study of cis-dischlorodiammineplatinum(II) in stage IVB Hodgkin's disease. Cancer Treat Rep (1979) 0.80
Bone marrow chromosome abnormalities in breast cancer in patients following adjuvant chemotherapy. Cancer Res (1980) 0.78
A clinicopathologic study of orbital and adnexal non-Hodgkin's lymphoma. Cancer (1979) 0.78
Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy. Cancer Treat Rep (1981) 0.78
Use of estrogen receptor data: recommendations for Iowa. J Iowa Med Soc (1980) 0.76
Successful therapy with methotrexate of a multicentric mixed lymphoma of the central nervous system. Cancer (1976) 0.76
Marrow neutrophil reserve after adjuvant chemotherapy for carcinoma of the breast. Cancer (1982) 0.76
An abbreviated phase II trial of thalicarpine. Cancer Treat Rep (1980) 0.75
Comparison of treatments for symptomatic Hodgkin's lymphoma employing decision analysis. Am J Clin Oncol (1984) 0.75
Failure of leucovorin rescue to prevent reactivation of a solar burn after high dose methotrexate. Cancer (1976) 0.75
Multimodality therapy of favorable prognosis non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (1983) 0.75
Cancer patient care in a general hospital. Mil Med (1975) 0.75
Monitoring central nervous system methotrexate levels via subcutaneous reservoir. Sources of errors in sampling and their avoidance. Cancer Clin Trials (1980) 0.75
Total body irradiation and cyclophosphamide, vincristine, prednisone in the treatment of favorable prognosis non-Hodgkin's lymphomas. Int J Radiat Oncol Biol Phys (1979) 0.75
Hepatic scan defects following radiotherapy for lymphoma. Clin Nucl Med (1978) 0.75
Letter: Radiotherapy-induced liver scan defects. J Nucl Med (1976) 0.75
Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma. Am J Med (1979) 0.75
An unusual manifestation of cryptococcal infection in a chronic lymphedematous arm. Med Pediatr Oncol (1982) 0.75
Decision analysis of estrogen and progesterone receptor testing in the management of breast cancer. Cancer Invest (1987) 0.75
Reasons for failure of MOPP to cure Hodgkin's disease: The importance of dose and schedule. Am J Clin Oncol (1982) 0.75
A decision-analysis methodology for consideration of morbidity factors in clinical decision-making. Am J Clin Oncol (1984) 0.75
Oral contraceptives and reproductive organ cancer risk. J Iowa Med Soc (1982) 0.75
Successful doxorubicin therapy of primary macroglobulinemia resistant to alkylating agents. Am J Hematol (1980) 0.75
A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkin's lymphoma. Cancer (1984) 0.75
Methotrexate with leucovorin rescue in the treatment of gynecologic malignancies. Preliminary report. Oncology (1975) 0.75
Leucovorin in combination chemotherapy of breast cancer. Clin Pharmacol Ther (1977) 0.75
Death and dying--oncology discussion group. J Psychiatr Nurs Ment Health Serv (1974) 0.75
Preparation and administration of chemotherapy. Haematological consequences for hospital-based nurses. Med Toxicol Adverse Drug Exp (1988) 0.75
Phase II study of ICRF-159 in non-Hodgkin's lymphomas. Cancer Treat Rep (1978) 0.75
Hodgkin's disease: premature report? Ann Intern Med (1972) 0.75
Sister chromatid exchange analysis in nurses handling antineoplastic drugs. Cancer Invest (1986) 0.75
Vinblastine, bleomycin, and cis-platin as salvage therapy for MOPP treated patients with Hodgkin's lymphoma. Cancer Invest (1984) 0.75
Granulocyte transfusion therapy: survival directly correlated with bone marrow recovery and the pathogenicity of the infectious organisms. Mil Med (1981) 0.75
Panel discussion: guidelines for planning, conducting, and monitoring clinical studies. Urology (1984) 0.75
Letter: Medical adrenalectomy with aminoglutethimide. JAMA (1975) 0.75
Delayed hypersensitivity in patients with cancer. N Engl J Med (1971) 0.75
Familial occurrence of von Willebrand's disease, thrombocytopenia, and severe gastrointestinal bleeding. Am J Med Sci (1973) 0.75
Erythema annulare centrifugum and Hodgkin's disease: association with disease activity. Arch Intern Med (1979) 0.75
Radiotherapy plus razoxane for advanced limited extent carcinoma of the lung. Cancer (1984) 0.75
Letter: The Philadelphia or short Y chromosome. JAMA (1974) 0.75
Possible radiation pericarditis precipitated by actinomycin D. Oncology (1974) 0.75
cis-dichlorodiammineplatinum(II) with and without ICRF-159 in non-Hodgkin's lymphoma. Cancer Treat Rep (1980) 0.75
Salvage therapy of aggressive non-Hodgkin's lymphoma with a combination of vinblastine, bleomycin, and cisplatin. Cancer (1984) 0.75